Wednesday, October 8, 2025

#India - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

{By Charles J. Sharp - Own work, from Sharp Photography, sharpphotography.co.uk, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=116380120}


Nineteen captive Painted Storks in the National Zoological Park, Delhi.

Source: WOAH, https://wahis.woah.org/#/in-review/6803

____


Comparative #risk #assessment of highly pathogenic avian #influenza #H5 viruses spread in French #broiler and layer sectors

 


Abstract

Since 2015, French poultry production is threatened almost every year by a reintroduction of highly pathogenic avian influenza H5 viruses. The duck sector was the most concerned by this crisis but other sectors such as broiler, layer and turkey were also affected by outbreaks. The objective of this work was to assess the risk of highly pathogenic avian influenza H5 virus transmission from one farm to another within the French broiler and layer production network. This study used the WOAH risk assessment framework. After drawing up a scenario tree of virus transmission from one farm to another, data were collected through a literature review or through experts elicitation. Three questionnaires were developed according to the experts field of expertise: avian influenza, broiler and layer sectors. The experts estimates were combined using a beta distribution weighted by their confidence level. A Monte Carlo iteration process was used to combine the different probabilities of the scenario tree and to assess the transmission risk. In the broiler sector, the highest transmission probabilities were observed if the exposed farm was an indoor broiler farm and the source a broiler farm (indoor or free-range). The high transmission probability between broiler farms integrated within the same association suggests that integration is an important risk factor. Person movement, transport of feed and manure management were the pathways with the highest transmission probabilities between two integrated indoor broiler farms with good biosecurity levels. In the layer sector, the highest transmission probabilities were observed if the source farm was a free-range farm and the exposed farm a production farm (indoor or free-range). The pathways with the highest transmission probabilities were egg transport and person movement. The sensitivity analysis showed that the exposed farm's biosecurity had a significant impact on the transmission probability. Our results provide an insight on the role of each type of farms in the virus spread within the French broiler and layer production sectors and will be useful for the implementation of control measures such as movement restriction or vaccination.


Competing Interest Statement

The authors have declared no competing interest.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.09.11.612235v5

____

Tuesday, October 7, 2025

Maternal #Influenza A Virus #Infection Induces Antiviral and Immune Dysregulation in the #Placenta and #Fetus Without Vertical Transmission

 


Abstract

Influenza A virus (IAV) infection during pregnancy is associated with stillbirth and preterm birth, possibly by disrupting placental and fetal immunity. To investigate this, pregnant pigtail macaques were inoculated with IAV [A/California/07/2009 (H1N1)] and examined at necropsy 5 days post-infection (N=11) versus uninfected controls (N=16). Stillbirth occurred in 18% of infected pregnancies but not in controls. While vertical transmission was not observed, low levels of viral RNA were detected in two placentas. Maternal IAV infection was associated with increased placental IL-1β and IFN-β levels and an upregulated type I interferon and integrated stress transcriptional response. Fetuses exposed to IAV had greater frequencies of innate immune cells in lymph nodes and CD4+ T cells in lungs. These results suggest that placental and fetal immune environments undergo immune activation independent of the severity of maternal lung infection. Influenza vaccination during pregnancy may protect against potentially harmful effects on fetal development.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

National Institutes of Health, https://ror.org/01cwqze88, AI164588, AI176777, AI007509

Foundation for the National Institutes of Health, https://ror.org/00k86s890, OD010425, TR002318, GM007266, OD011123

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.10.06.675688v1

____

#Iran - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

 


A backyard village poultry in Ardebil Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6849

____

#Poland - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

 


{By JJ Harrison - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=5014480}

A slaugthter geese farm in Wielkopolskie Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6852

____

#Sweden - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


{By Aviceda - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=4017548}

___

In accordance with the WOAH Terrestrial Animal Health Code, Article 10.4.1, point 4, this outbreak does not change the disease-free status of Sweden as these are wild birds, and therefore do not fall within the WOAH definition of poultry.

A Mediterranean Gull was found dead. It was sent to the Swedish Veterinary Agency for laboratory analysis as part of the national surveillance program for avian influenza.

Source: WOAH, https://wahis.woah.org/#/in-review/6853

____

Host Switching #Mutations in #H5N1 #Influenza Hemagglutinin Suppress Site-specific Activation Dynamics

 


Abstract

Increase in the occurrence of human H5N1 spillover infections resulting from dissemination of highly pathogenic avian influenza (HPAI) virus into bird and mammal populations raises concerns about HPAI adapting to become human transmissible. Studies identified hemagglutinin (HA) acid stability and receptor preference as essential traits that shape host tropism. Mutations that increase HA stability and affinity for α-2,6-linked sialic acids have been shown to confer airborne transmissibility in a ferret model, however mechanisms of activation of H5 subtype HA have not been probed and the effect of adaptive mutations on HA function has been largely inferred from static structures. Here, we use hydrogen/deuterium-exchange mass spectrometry to dissect activation dynamics for two ancestral HPAI H5 HA, their matched HA with adaptive mutations, and a contemporary H5 HA. By measuring dynamics, we identify variation in active site flexibility among the HA and demonstrate that adaptive mutations result in suppression of fusion peptide dynamics and stabilization of a key subunit interface involved in activation. The contemporary H5 isolated from a recent human spillover case exhibits a relatively protected fusion peptide and moderately depressed pH of activation compared to the HAs examined in this study. Our studies of activation dynamics in the H5 HAs in conjunction with prior analysis of H1 and H3 HA reveal subtype-specific patterns that correlate with adaptive mutation sites and indicate underlying physical constraints on influenza HA adaptation.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

NIH Common Fund, https://ror.org/001d55x84, R01AI165808, T32-GM007750

Hope Barnes Fellowship

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.10.06.680362v1

____

Monday, October 6, 2025

Re-emergence of #chikungunya virus in #China by 2025: What we know and what to do?

 


Abstract

In July 2025, China witnessed its most significant chikungunya virus (CHIKV) outbreak since 2010. As of August 1, with over 6,000 cases reported in Foshan city, Guangdong Province. Although the clinical manifestations have been relatively mild, the rapid transmission within communities warrants our attention. In this context, we emphasize our current knowledge and the necessary actions to take. Specifically, we identify critical gaps in CHIKV control efforts and assess the effectiveness of current measures. These include vector management strategies, viral genomic surveillance, the deployment of newly approved vaccines, and the development of antiviral agents. Overall, to effectively control the epidemic of CHIKV, we require a comprehensive and multifaceted strategy for its prevention and management.

Source: PLoS Pathogens, https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013556

____

#Germany - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

 


A poultry farm in Thüringen Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6844

____

#Denmark - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


According to article 10.4.1.4 of the Terrestrial Animal Health Code, Member Countries should not impose bans on the trade in poultry commodities in response to notification on the presence of any influenza A virus in birds other than poultry.

A wild black-headed gull in Vordingborg. 

Source: WOAH, https://wahis.woah.org/#/in-review/6846

____

Protective efficacy of the UniFluVec #influenza #vaccine vector against the highly pathogenic influenza A/Indonesia/5/2005 #H5N1 strain in #ferrets

 


Highlights

• UniFluVec, an H1N1pdm vaccine candidate, includes NS1 and NEP modifications to boost attenuation and immunity.

• UniFluVec protects ferrets from H5N1, enhancing clearance, limiting lung damage, and ensuring 100 % survival after one dose.

• Replication-deficient UniFluVec shows cross-protection, supporting its potential as a pre-pandemic intranasal vaccine.


Abstract

Background

The emergence of new influenza strains with unpredictable antigenic properties poses a significant vaccination challenge. The increasing incidence of human H5 infections underscores the urgent need for effective pre-pandemic vaccines.

Methods

The UniFluVec and UniFluVec-wtNS1 viruses were designed as H1N1pdm vaccine candidates. Both viruses contained a heterologous A/Singapore/1/57-like (H2N2) NEP gene, which served as an attenuation factor. UniFluVec additionally carried a truncated to 124 amino acids NS1 gene, and an insertion of conserved influenza sequences. UniFluVec-wtNS1 retained the wild-type NS1 gene. The impact of NS1 and NEP modifications on attenuation and phenotypic markers was assessed in cells and mice. Safety and prophylactic efficacy were assessed in ferrets following a single intranasal immunisation with the maximum feasible dose (8.7 log10 EID50), followed by challenge with the highly pathogenic avian influenza virus (HPAIV) A/Indonesia/5/2005 (H5N1).

Results

Modifications in NS1 and NEP independently and synergistically induced a temperature-sensitive phenotype and enhanced type I/II interferon response, resulting in a highly attenuated vaccine profile. UniFluVec, incorporating both modifications within the NS genomic segment, demonstrated superior viral clearance, reducing lung damage, and ensuring 100 % survival in infected animals.

Conclusion

The replication-deficient UniFluVec vector demonstrates safety, immunogenicity, and protective efficacy against the heterologous HPAIV strain in ferrets following a single intranasal administration.

Source: Vaccine, https://www.sciencedirect.com/science/article/pii/S0264410X25010928?via%3Dihub

____

Sunday, October 5, 2025

Highly pathogenic avian #influenza in South #America, 2022-25: temporality, affected #species, and southwards #expansion to #Antarctic region.

 


Abstract

The H5N1 highly pathogenic avian influenza (HPAI) virus has caused severe global losses, reaching South America in 2022 and Antarctica in 2024. Here we synthesize outbreak reports submitted to the World Organization for Animal Health (WOAH) by South American countries and document the virus's unprecedented expansion into Antarctica, affecting wild birds, wild mammals, and domestic poultry. More than 6 million domestic birds died or were culled, mostly from commercial operations. Of the 11 South American countries that reported H5N1 to WOAH, 10 reported infections in wild birds, spanning 104 species, 59.62% of which are migratory and predominantly non-trans-equatorial. Marine mammal cases occurred after wild bird detections, with the South American sea lion (Otaria flavescens) most affected, and several Antarctic bird species with migratory behavior were also reported in South America. To complement outbreak data, we examined available genomic sequences through phylogenetic and time-calibrated Bayesian analyses, which revealed multiple introduction events, viral diversity across regions, and evidence of interspecies transmission dynamics. These findings highlight the extensive ecological reach of H5N1 in the Southern Hemisphere and underscore the urgent need for a One Health approach that strengthens wildlife and backyard-poultry surveillance while fostering coordinated regional action to control and prevent further spread of HPAI.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.10.03.680239v1

____

Paradise, Tintoretto (c. 1592)

 


Public Domain.

Source: WikiArt, https://www.wikiart.org/en/tintoretto/paradise

____

Saturday, October 4, 2025

First serological #evidence of equine #coronavirus and #SARS-CoV-2 in #horses in North #Africa

 


Abstract

Viral diseases cause significant economic losses within the equine population. Horses are susceptible to equine coronavirus (ECoV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), although only ECoV has been associated to clinical disease. The aim of this study was to investigate, for the first time in Algeria, the seroprevalence of ECoV and SARS-CoV-2 antibodies and the prevalence of ECoV infection in horses. In 2022, a total of 299 serum samples was collected from horses aged 1 to 27 years. Serological analysis for the presence of ECoV and SARS-CoV-2 was performed using a validated in-house and a commercially available ELISA, respectively. In addition, fecal samples of these animals were tested for the presence of ECoV RNA by RT-qPCR. SARS-CoV-2-ELISA positive sera with high S/P ratios and negative samples close to the doubtful threshold were retested using a virus neutralization test (VNT). The seroprevalence of ECoV and SARS-CoV-2 in the tested horses was 63.5% (190/299) and 4.3% (13/299), respectively. Among CoVs-seropositive horses, six were seropositive for both ECoV and SARS-CoV-2, thus 6/10 sera were VNT positive, including two ELISA-negative samples for SARS-CoV-2. ECoV seroprevalence varied according to age, breed and sex. None of the fecal samples tested positive for ECoV. Antibodies against SARS-CoV-2 were confirmed by VNT in six samples (2%). One SARS-CoV-2-positive serum tested by ELISA and confirmed through VNT was cytotoxic for VERO cells. This study is the first to report the circulation of ECoV and SARS-CoV-2 in the Algerian horse population. Further studies are necessary to isolate and obtain molecular characterisation of ECoV and SARS-CoV-2 from horses in Algeria.

Source: Veterinary Research Communications, https://link.springer.com/article/10.1007/s11259-025-10928-0

____

History of Mass Transportation: The Snowdon Mountain Railway Steam Locomotive (1922)

 


Von A.M.Hurrell - Photographer - A.M.Hurrell, CC BY 2.5, https://commons.wikimedia.org/w/index.php?curid=423388

Source: Wikipedia, https://de.wikipedia.org/wiki/Schweizerische_Lokomotiv-_und_Maschinenfabrik

____

#Coronavirus Disease Research #References (by AMEDEO, October 4 '25)

 


    Int J Infect Dis

  1. TENG Z, Li L, Che T, Liang J, et al
    A Novel Balamuthia Lineage Causing Fatal Granulomatous Amoebic Encephalitis in an Immunocompetent Infant.
    Int J Infect Dis. 2025 Sep 17:108063. doi: 10.1016/j.ijid.2025.108063.
    PubMed         Abstract available


    J Med Virol

  2. PLICANTI E, Deiana A, Nottoli S, Lottini G, et al
    A Pyrido-Quinoxaline Derivative That Downregulates Reticulon 3 Protein Exhibits Potent Antiviral Activity Against Zika Virus.
    J Med Virol. 2025;97:e70605.
    PubMed         Abstract available


    J Virol

  3. TSUJINO S, Tsuda M, Nao N, Okumura K, et al
    Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.
    J Virol. 2025 Sep 23:e0090825. doi: 10.1128/jvi.00908.
    PubMed         Abstract available

  4. HAMMER E, Flynn C, Rossler J, Erder J, et al
    Prediction of COVID-19 disease progression by multiparametric analysis of circulating extracellular vesicles with flow cytometry.
    J Virol. 2025 Sep 23:e0118925. doi: 10.1128/jvi.01189.
    PubMed         Abstract available


    JAMA

  5. ANDERER S
    Nasal Spray May Help Prevent COVID-19 Infection.
    JAMA. 2025 Sep 19. doi: 10.1001/jama.2025.13883.
    PubMed        


    Nature

  6. LENHARO M, Ledford H
    Hotly anticipated US vaccine meeting ends with confusion - and a few decisions.
    Nature. 2025 Sep 20. doi: 10.1038/d41586-025-03054.
    PubMed        


    Radiologia (Engl Ed)

  7. SORIANO AGUADERO I, Ezponda Casajus A, Paternain Nuin A, Vidorreta M, et al
    Prognostic value of the extent of affected lung parenchyma in COVID-19 pneumonia patients: Visual estimation versus automatic quantification by artificial intelligence.
    Radiologia (Engl Ed). 2025;67:101612.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 4 '25)

 


    Am J Med

  1. WAHID L, Kwon T, Kreuziger LB, Kasthuri RS, et al
    Extended Thromboprophylaxis in Patients Hospitalized with COVID-19 at Time of Discharge is Not Associated with Improvement in Quality of Life.
    Am J Med. 2025;138:1464-1468.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. ZHANG L, Li Y, Ye K, Wang P, et al
    Article I. metformin affects H1N1-induced apoptosis in lung epithelial cells by the miR-130a-5p-regulated PI3K/AKT signaling pathway.
    Biochem Biophys Res Commun. 2025;782:152526.
    PubMed         Abstract available


    J Gen Virol

  3. HA Y, Lee YH, Jo HS, Kwon TW, et al
    Susceptibility of different mouse strains to SARS-CoV-2 spike receptor-binding domain protein-induced lung inflammation: a comparative study.
    J Gen Virol. 2025;106.
    PubMed         Abstract available


    J Infect Dis

  4. GAILLET A, Layese R, Fourati S, Celante H, et al
    Clinical Phenotypes and Outcomes Associated With Respiratory Syncytial Virus Infection in Critically Ill Patients: A Retrospective Multicenter Cohort Study in Greater Paris Area Hospitals, 2017-2023.
    J Infect Dis. 2025;232:679-690.
    PubMed         Abstract available

  5. LI K, Bont LJ, Weinberger DM, Pitzer VE, et al
    Relating In Vivo Respiratory Syncytial Virus Infection Kinetics to Host Infectiousness in Different Age Groups.
    J Infect Dis. 2025;232:691-699.
    PubMed         Abstract available

  6. LI K, Pitzer VE, Weinberger DM
    Exploring RSV Transmission Patterns in Different Age Groups in the United States.
    J Infect Dis. 2025;232:700-708.
    PubMed         Abstract available

  7. DOSS CR, Osborn MJ, Stark S, Rhein J, et al
    Wastewater Measures of SARS-CoV-2 Accurately Predict Frequency of Symptomatic Infections in the Community.
    J Infect Dis. 2025;232:e459-e465.
    PubMed         Abstract available

  8. HAMILTON F, Butler-Laporte G, Davey Smith G
    Mendelian Randomization and Infection: Pitfalls and Promises.
    J Infect Dis. 2025;232:525-533.
    PubMed         Abstract available

  9. WANG C, Yuan HY, Lau EHY, Cowling BJ, et al
    Impact of Population Immunity and Public Health Measures on the Transmission of Omicron Subvariants BA.2 and BA.5 in Hong Kong.
    J Infect Dis. 2025;232:e476-e485.
    PubMed         Abstract available

  10. KNOX JJ, Lee I, Blumberg EA, Rosenfeld AM, et al
    B-Cell Subset Representation Predicts SARS-CoV-2 Vaccine Response in Solid Organ Transplant Recipients.
    J Infect Dis. 2025 Jun 3:jiaf250. doi: 10.1093.
    PubMed         Abstract available

  11. LIM SY, Lee J, Kwon JS, Chang E, et al
    Disparate kinetics of viable virus shedding in immunocompromised patients: SARS-CoV-2 versus influenza virus - a prospective real-world cohort study.
    J Infect Dis. 2025 Sep 15:jiaf479. doi: 10.1093.
    PubMed         Abstract available

  12. ALEMNJI G, Sangthong A, Espy N, Bartee M, et al
    PEPFAR Laboratory Implementation Strategy as a Component of PEPFAR's 5-Year Strategy.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  13. OKOYE M, Okoi C, Espy N, Mba N, et al
    Leveraging PEPFAR- and Global Fund-Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria.
    J Infect Dis. 2025;232.
    PubMed         Abstract available


    J Virol

  14. MA Y, Ye C, Khalil AM, Mahmoud SH, et al
    A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants.
    J Virol. 2025 Aug 7:e0082125. doi: 10.1128/jvi.00821.
    PubMed         Abstract available

  15. KARIMI A, Lieber CM, Sakamoto K, Plemper RK, et al
    SARS-CoV-2 causes chronic lung inflammation and impaired respiratory capacity in aged Roborovski dwarf hamsters.
    J Virol. 2025 Aug 11:e0075525. doi: 10.1128/jvi.00755.
    PubMed         Abstract available

  16. BATY JJ, Drozdick AK, Pfeiffer JK
    Pseudomonas aeruginosa rhamnolipids stabilize human rhinovirus 14 virions.
    J Virol. 2025;99:e0093125.
    PubMed         Abstract available

  17. HU J, Zheng H, Ran W, Wang X, et al
    Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
    J Virol. 2025 Aug 19:e0123125. doi: 10.1128/jvi.01231.
    PubMed         Abstract available

  18. EL ZOWALATY ME, Taylor LJ, Son Y, Lee H, et al
    Discovery, phylogenetic, and comparative genomic analysis of novel avian gammacoronaviruses identified in feral pigeons (Columba livia domestica).
    J Virol. 2025 Aug 20:e0111225. doi: 10.1128/jvi.01112.
    PubMed         Abstract available

  19. ZHANG H, Deng X, Dai R, Fu J, et al
    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.
    J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688.
    PubMed         Abstract available

  20. CHI X, Liang X, Vaddadi K, Zhang X, et al
    SARS-CoV-2 Nsp15 endoribonuclease subverts host defenses to enhance viral fitness in lung cells.
    J Virol. 2025 Aug 21:e0117525. doi: 10.1128/jvi.01175.
    PubMed         Abstract available

  21. HU Z, Tian S, Zhou Y, Wang Y, et al
    Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.
    J Virol. 2025 Aug 26:e0090325. doi: 10.1128/jvi.00903.
    PubMed         Abstract available

  22. VERMA A, Kamboj H, Kumar G, Khandelwal N, et al
    TGF-beta inhibitor SB431542 suppresses SARS-CoV-2 replication through multistep inhibition.
    J Virol. 2025 Aug 29:e0052925. doi: 10.1128/jvi.00529.
    PubMed         Abstract available

  23. GRACIE NP, Aggarwal A, Luo R, Spicer M, et al
    An RGD motif on SARS-CoV-2 Spike induces TGF-beta signaling and downregulates interferon.
    J Virol. 2025 Sep 4:e0043525. doi: 10.1128/jvi.00435.
    PubMed         Abstract available

  24. JANZEN GM, Inderski BT, Chang J, Arendsee ZW, et al
    Sources and sinks of influenza A virus genomic diversity in swine from 2009 to 2022 in the United States.
    J Virol. 2025;99:e0054125.
    PubMed         Abstract available

  25. ZHU B, Fung K, Feng HH, Beatty JA, et al
    The hemagglutinin proteins of clades 1 and 2.3.4.4b H5N1 highly pathogenic avian influenza viruses exhibit comparable attachment patterns to avian and mammalian tissues.
    J Virol. 2025 Sep 23:e0097625. doi: 10.1128/jvi.00976.
    PubMed         Abstract available


    PLoS Comput Biol

  26. LIM D, Ko KT, Hong H, Lee H, et al
    A history-dependent approach for accurate initial condition estimation in epidemic models.
    PLoS Comput Biol. 2025;21:e1013438.
    PubMed         Abstract available

  27. HODGSON D, Hay J, Jarju S, Jobe D, et al
    serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data.
    PLoS Comput Biol. 2025;21:e1013467.
    PubMed         Abstract available


    PLoS Med

  28. PREISS A, Bhatia A, Aragon LV, Baratta JM, et al
    Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia.
    PLoS Med. 2025;22:e1004711.
    PubMed         Abstract available


    PLoS One

  29. SALDIVAR L, Rajabi T, Li W, Lopa S, et al
    Recurrent venous thromboembolism and clot distribution in COVID-19 infection: A review by variant type.
    PLoS One. 2025;20:e0331283.
    PubMed         Abstract available

  30. SAW HW, Kapteyn A
    Personality traits, panel tenure, survey topic, and context as predictors of survey nonresponse patterns in high-frequency online longitudinal surveys.
    PLoS One. 2025;20:e0332902.
    PubMed         Abstract available

  31. BASHORUN AO, Kotei L, Jallow AF, Jawla O, et al
    Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol.
    PLoS One. 2025;20:e0332842.
    PubMed         Abstract available

  32. SHIMIZU IS, Freire SF, Sousa MLA, Ferreira JC, et al
    Knowledge, attitudes, and practice about protective ventilation among physical therapists.
    PLoS One. 2025;20:e0331949.
    PubMed         Abstract available

  33. LU W, Liu Q, Li H
    Confidence, animal spirits, and the macroeconomy in China: Based on mixed-frequency data models.
    PLoS One. 2025;20:e0332909.
    PubMed         Abstract available

  34. WANG J, Liu Y, Li N, Zhu Y, et al
    Hand hygiene after the COVID-19 pandemic: Is it still at a high level?
    PLoS One. 2025;20:e0332634.
    PubMed         Abstract available

  35. EDU-QUANSAH DA, Bandoh DA, Edu-Quansah EP, Appiah AB, et al
    Evaluation of the performance of the Influenza-like Illness (ILI) surveillance system in the Okai Koi North District, Greater Accra Region, 2022.
    PLoS One. 2025;20:e0332334.
    PubMed         Abstract available

  36. BOEVER C, Zech E, Arcand L, Verdon C, et al
    What does it mean to have experienced the death of a relative in a context of social and funeral restrictions? Lessons from the pandemic for bereavement research and clinical practice.
    PLoS One. 2025;20:e0331946.
    PubMed         Abstract available

  37. SWANSON B, Bishop-Royse J, Keshavarzian A, Balk R, et al
    Examination of unique volatile organic compound signatures in nasopharyngeal test swab viral transport media using an electronic nose.
    PLoS One. 2025;20:e0332399.
    PubMed         Abstract available

  38. REITERMAN M, Chin AI, Bang H
    Adverse outcomes post-COVID-19 hospitalization among ESRD patients: A retrospective cohort study in 5 California university medical centers.
    PLoS One. 2025;20:e0332203.
    PubMed         Abstract available

  39. PAYNE LA, Edelman A, Darney BG, Benhar E, et al
    Brief report: Older adolescents and young adults may be at higher risk for changes to menstrual cycle length with COVID-19 vaccination.
    PLoS One. 2025;20:e0331346.
    PubMed         Abstract available

  40. POLISHCHUK V, Kostinov capital EM, Cyrillic, Ryzhov capital A, Cyrillic, Dagil Y, et al
    Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates.
    PLoS One. 2025;20:e0332346.
    PubMed         Abstract available

  41. PEREZ-MORALES AM, Jimenez-Juarez RN, Morales-Rios OM, Reyes-Lopez A, et al
    Antibacterial consumption before, during, and after the COVID-19 pandemic in a tertiary care pediatric hospital in Mexico.
    PLoS One. 2025;20:e0329220.
    PubMed         Abstract available

  42. KAYA MG, Karaman K
    Clinical parameters associated with mortality in elderly patients with COVID-19.
    PLoS One. 2025;20:e0332800.
    PubMed         Abstract available

  43. MONGE M, Hurtado R, Infante J
    Time trends and persistence of the return difference between growth and value investment strategies.
    PLoS One. 2025;20:e0332690.
    PubMed         Abstract available

  44. WANG Y, Gao YD, Jiang CH, Xi Y, et al
    Characterisation of a novel chicken-derived H3N3 avian influenza virus detected in China in 2023: Pathogenicity and immunogenicity.
    PLoS One. 2025;20:e0332213.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  45. YOSHIDA A, Uekusa Y, Suzuki T, Bauer M, et al
    Enhanced visualization of influenza A virus entry into living cells using virus-view atomic force microscopy.
    Proc Natl Acad Sci U S A. 2025;122:e2500660122.
    PubMed         Abstract available


    Vaccine

  46. SCHERM MJ, Holzl R, Gonzalez-Dominguez I, Hjorth R, et al
    Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.
    Vaccine. 2025;64:127671.
    PubMed         Abstract available

  47. HARIT D, Sawant S, Spreng RL, Gurley S, et al
    Qualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials.
    Vaccine. 2025;64:127699.
    PubMed         Abstract available

  48. HUI S, He R, Li H, Li Y, et al
    Revealing dynamic transcriptomic and immune cell signatures underlying heterogeneous responses to influenza vaccination.
    Vaccine. 2025;64:127777.
    PubMed         Abstract available

  49. PALACHE B, Fyyaz H, Thomson D, Taylor B, et al
    The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022-2023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination.
    Vaccine. 2025;64:127747.
    PubMed         Abstract available

  50. SARTORI AL, Buffarini R, Bertoldi AD, da Silveira MF, et al
    Association between maternal influenza vaccination and childhood vaccination among participants of the 2015 Pelotas (Brazil) birth cohort.
    Vaccine. 2025;64:127761.
    PubMed         Abstract available


    Virus Res

  51. SHI X, Wang J, Li C, Du S, et al
    Single amino acid substitution at position 614 in SARS-CoV-2 Spike Protein alters viral assembly and infectivity.
    Virus Res. 2025;360:199624.
    PubMed         Abstract available

  52. GONG T, Zhang X, Lin H, Li J, et al
    Mutation profiling, evolution analysis, molecular dynamics simulation, and functional characterization of Omicron sub-strains.
    Virus Res. 2025;360:199626.
    PubMed         Abstract available

  53. RAMASAMY S, Bustamante F, LaBella LC, Cole SD, et al
    Spillover of SARS-CoV-2 to domestic dogs in COVID-19-positive households: A one health surveillance study.
    Virus Res. 2025;360:199629.
    PubMed         Abstract available

  54. CHAVOIX C, Massin P, Briand FX, Louboutin K, et al
    Identification of H1N2 influenza viruses in turkeys after spillover from swine and in vitro characterization.
    Virus Res. 2025 Sep 21:199634. doi: 10.1016/j.virusres.2025.199634.
    PubMed         Abstract available

Friday, October 3, 2025

#Chikungunya virus disease - #Global #situation (#WHO D.O.N., Summary, Oct. 3 '25)

 




Situation at a glance

In 2025, a resurgence of chikungunya virus (CHIKV) disease was noted in a number of countries, including some that had not reported substantial case numbers in recent years. 

Between 1 January and 30 September 2025, a total of 445 271 suspected and confirmed CHIKV disease cases and 155 deaths were reported globally from 40 countries, including autochthonous and travel imported cases. 

Some WHO Regions are experiencing significant increases in case numbers compared to 2024, although others are currently reporting lower case numbers. 

This uneven distribution of cases across regions makes it challenging to characterize the situation as a global rise, however, given the ongoing outbreaks reported globally in 2025, the potential for further spread remains significant

CHIKV disease can be introduced into new areas by infected travelers and local transmission may be established if there is the presence of Aedes mosquito and a susceptible population. 

The risk is heightened by limited population immunity in previously unaffected areas, favorable environmental conditions for vector breeding, gaps in surveillance and diagnostic capacity, and increased human mobility and trade. 

Strengthening disease surveillance, enhancing vector surveillance and control, and improving public health preparedness are essential to mitigate the risk of further transmission. 

Prior to 2025, current or previous autochthonous transmission of CHIKV has been reported from 119 countries and territories. 

A total of 27 countries and territories across six WHO regions have established competent populations of Aedes aegypti mosquitoes but have not yet reported autochthonous CHIKV transmission. 

Additional countries have established populations of Aedes albopictus mosquitoes, which can also transmit CHIKV, and in which transmission efficiency is enhanced for CHIKV lineages with the E1 226V mutation

The presence of these vectors poses a continuous threat of chikungunya introduction and spread in previously unaffected areas. 

Increased CHIKV transmission is driven by multiple factors that include: 

- the expanded geographic distribution of Aedes mosquitoes related to transportation in conveyances and 

- climate change

- unplanned urbanization

- poor water management, and 

- weakened vector surveillance and control. 

CHIKV disease typically causes high population attack rates. In smaller settings such as islands, the transmission dynamics can be temporarily interrupted once a proportion of the population becomes infected and subsequently immune. 

In larger populations however, where enough individuals remain immunologically susceptible, transmission can persist over time, leading to sustained outbreaks

These outbreaks often place a significant burden on healthcare systems due to the number of affected individuals. 

Countries differ in their ability to detect and report chikungunya and other vector-borne diseases, with many outbreaks identified only retrospectively, hindering effective public health responses. 

Early detection of cases, particularly in persons at risk for severe CHIKV disease, and timely access to appropriate medical care are essential for minimizing clinical complications and reducing mortality. 

The variation in distribution of cases across regions highlights the importance of continued investment in surveillance, preparedness, and response capacities to address evolving regional dynamics. 

WHO continues to call on all countries to strengthen their healthcare and laboratory systems to enable rapid detection, timely reporting, and effective response to chikungunya outbreaks.

(...)

Source: World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581

____

#Italy, Integrated #WNV & #USUV #Surveillance - Weekly Bulletin No. 12, 2 October 2025: 38 new confirmed cases (Summary)

 


{Summary}

-- During current epidemiological week (from 25 September to 1rst October 2025), 38 new confirmed human infection with West Nile Virus have been reported. 

-- Since the beginning of the epidemic season, 718 confirmed cases have been recorded in Italy (they were 680 in the last bulletin), of these: 

- 341 were West Nile Neuroinvasive Disease (WNND): 15 in Piedmont, 51 Lombardy, 30 Veneto, 4 Friuli-Venezia Giulia, 1 Liguria, 27 Emilia-Romagna, 11 Tuscany, 1 Marche, 84 Latium, 2 Molise, 79 Campania, 2 Apulia, 2 Basilicata, 5 Calabria, 2 Sicily, 25 Sardinia, 

- 57 were asymptomatic cases in blood donors

- 309 were West Nile Fever cases (1 imported from Kenya, 1 Egypt, and one Maldives), 

- 4 asymptomatic cases, 

- 7 unspecified cases. 

-- Among confirmed cases, there have been 49 fatalities: 7 in Piedmont, 5 Lombardy, 2 Emilia-Romagna, 18 Latium, 14 Campania, 2 Calabria, 1 Sardinia. 

- The Case-Fatality Rate in WNND cases was 14.4% (it was 20% in 2018 and 14% in 2024

-- This season 10 confirmed Usutu virus human infections have been recorded: 2 in Piedmont, 3 Lombardy, 2 Veneto, 3 Latium.

(...)

Source: High Institute of Health, https://www.epicentro.iss.it/westnile/bollettino/Bollettino_WND_2025_12.pdf

____

Fatal #Human #H3N8 #Influenza Virus has a Moderate #Pandemic #Risk

 


Abstract

In China, low pathogenic avian influenza (LPAI) H3N8 virus is widespread among chickens and has recently caused three zoonotic infections, with the last one in 2023 being fatal. Here we evaluated the relative pandemic risk of this 2023 zoonotic H3N8 influenza virus, utilizing our previously published decision tree. Serological analysis indicated that a large proportion of the human population does not have any cross-neutralizing antibodies against this H3N8 strain. LPAI H3N8 displayed a dual affinity for a2-3 and a2-6 sialic acids and replicated efficiently in human bronchial epithelial cells. Furthermore, we observed H3N8 transmission via direct contact but not aerosols to ferrets with pre-existing H3N2 immunity. Although pre-existing H3N2 immunity resulted in a shortened disease course in ferrets, it did not reduce disease severity or replication in the respiratory tract. This study suggests that this zoonotic H3N8 strain has moderate pandemic potential and emphasizes the continued need for avian influenza surveillance.


Competing Interest Statement

The authors have declared no competing interest.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.10.02.679960v1

____

My New Space

Most Popular Posts